Zai Lab (ZLAB) announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics to use MediLink’s Tmalin antibody-drug conjugate platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab. ZL-6201 has demonstrated preclinical data with an IND expected to be filed in 2025.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB: